MFG-E8 (LACTADHERIN): a novel marker associated with cerebral amyloid angiopathy

Paula Marazuela, Montse Solé, Anna Bonaterra-Pastra, Jesús Pizarro, Jessica Camacho, Elena Martínez-Sáez, H. Bea Kuiperij, Marcel M. Verbeek, Anna M. de Kort, Floris H.B.M. Schreuder, Catharina J.M. Klijn, Laura Castillo-Ribelles, Olalla Pancorbo, David Rodríguez-Luna, Francesc Pujadas, Pilar Delgado, Mar Hernández-Guillamon

Producció científica: Article en revista indexadaArticleAvaluat per experts

10 Cites (Scopus)

Resum

Brain accumulation of amyloid-beta (Aβ) is a crucial feature in Alzheimer´s disease (AD) and cerebral amyloid angiopathy (CAA), although the pathophysiological relationship between these diseases remains unclear. Numerous proteins are associated with Aβ deposited in parenchymal plaques and/or cerebral vessels. We hypothesized that the study of these proteins would increase our understanding of the overlap and biological differences between these two pathologies and may yield new diagnostic tools and specific therapeutic targets. We used a laser capture microdissection approach combined with mass spectrometry in the APP23 transgenic mouse model of cerebral-β-amyloidosis to specifically identify vascular Aβ-associated proteins. We focused on one of the main proteins detected in the Aβ-affected cerebrovasculature: MFG-E8 (milk fat globule-EGF factor 8), also known as lactadherin. We first validated the presence of MFG-E8 in mouse and human brains. Immunofluorescence and immunoblotting studies revealed that MFG-E8 brain levels were higher in APP23 mice than in WT mice. Furthermore, MFG-E8 was strongly detected in Aβ-positive vessels in human postmortem CAA brains, whereas MFG-E8 was not present in parenchymal Aβ deposits. Levels of MFG-E8 were additionally analysed in serum and cerebrospinal fluid (CSF) from patients diagnosed with CAA, patients with AD and control subjects. Whereas no differences were found in MFG-E8 serum levels between groups, MFG-E8 concentration was significantly lower in the CSF of CAA patients compared to controls and AD patients. Finally, in human vascular smooth muscle cells MFG-E8 was protective against the toxic effects of the treatment with the Aβ40 peptide containing the Dutch mutation. In summary, our study shows that MFG-E8 is highly associated with CAA pathology and highlights MFG-E8 as a new CSF biomarker that could potentially be used to differentiate cerebrovascular Aβ pathology from parenchymal Aβ deposition.

Idioma originalAnglès
Número d’article154
RevistaActa Neuropathologica Communications
Volum9
Número1
DOIs
Estat de la publicacióPublicada - de des. 2021
Publicat externament

Fingerprint

Navegar pels temes de recerca de 'MFG-E8 (LACTADHERIN): a novel marker associated with cerebral amyloid angiopathy'. Junts formen un fingerprint únic.

Com citar-ho